Full Text View
Tabular View
Study Results
Related Studies
Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
This study has been completed.
Study NCT00723827   Information provided by Merck

First Received on July 25, 2008.   Last Updated on December 5, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Glioblastoma
Glioma
Astrocytoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Interventions listed in this trial
Temozolomide
Radiotherapy
Additional drug interventions recognized in this trial
Dacarbazine
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Merck


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services